| Literature DB >> 32525856 |
Kathleen P Hartnett, Aaron Kite-Powell, Jourdan DeVies, Michael A Coletta, Tegan K Boehmer, Jennifer Adjemian, Adi V Gundlapalli.
Abstract
On March 13, 2020, the United States declared a national emergency to combat coronavirus disease 2019 (COVID-19). As the number of persons hospitalized with COVID-19 increased, early reports from Austria (1), Hong Kong (2), Italy (3), and California (4) suggested sharp drops in the numbers of persons seeking emergency medical care for other reasons. To quantify the effect of COVID-19 on U.S. emergency department (ED) visits, CDC compared the volume of ED visits during four weeks early in the pandemic March 29-April 25, 2020 (weeks 14 to 17; the early pandemic period) to that during March 31-April 27, 2019 (the comparison period). During the early pandemic period, the total number of U.S. ED visits was 42% lower than during the same period a year earlier, with the largest declines in visits in persons aged ≤14 years, females, and the Northeast region. Health messages that reinforce the importance of immediately seeking care for symptoms of serious conditions, such as myocardial infarction, are needed. To minimize SARS-CoV-2, the virus that causes COVID-19, transmission risk and address public concerns about visiting the ED during the pandemic, CDC recommends continued use of virtual visits and triage help lines and adherence to CDC infection control guidance.Entities:
Mesh:
Year: 2020 PMID: 32525856 PMCID: PMC7315789 DOI: 10.15585/mmwr.mm6923e1
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
FIGURE 1Weekly number of emergency department (ED) visits — National Syndromic Surveillance Program, United States,* January 1, 2019– May 30, 2020†
* Hawaii, South Dakota, and Wyoming are not included.
† Vertical lines indicate the beginning and end of the 4-week coronavirus disease 2019 (COVID-19) early pandemic period (March 29–April 25, 2020) and the comparison period (March 31–April 27, 2019).
FIGURE 2Emergency department (ED) visits, by age group (A) and U.S. Department of Health and Human Services (HHS) region* (B) — National Syndromic Surveillance Program, United States,† March 31–April 27, 2019 (comparison period) and March 29–April 25, 2020 (early pandemic period)
* Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, and Vermont; Region 2: New Jersey and New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, and West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, and Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, and Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, and Texas; Region 7: Iowa, Kansas, Missouri, and Nebraska; Region 8: Colorado, Montana, North Dakota, and Utah; Region 9: Arizona, California, and Nevada; Region 10: Alaska, Idaho, Oregon, and Washington.
† Hawaii, South Dakota, and Wyoming are not included.
Differences in mean weekly numbers of emergency department (ED) visits* for diagnostic categories with the largest increases or decreases† and prevalence ratios§ comparing the proportion of ED visits in each diagnostic category, for categories with the highest and lowest ratios — National Syndromic Surveillance Program, United States,¶ March 31–April 27, 2019 (comparison period) and March 29–April 25, 2020 (early pandemic period)
| Diagnostic category | Change in mean no. of weekly ED visits* | Prevalence ratio (95% CI)§ |
|---|---|---|
|
| ||
| Exposure, encounters, screening, or contact with infectious disease** | 18,834 | 3.79 (3.76–3.83) |
| COVID-19 | 17,774 | — |
| Other general signs and symptoms** | 4,532 | 1.87 (1.86–1.89) |
| Pneumonia (except that caused by tuberculosis)** | 3,911 | 1.91 (1.90–1.93) |
| Other specified and unspecified lower respiratory disease** | 1,506 | 1.99 (1.96–2.02) |
| Respiratory failure, insufficiency, arrest** | 776 | 1.76 (1.74–1.78) |
| Cardiac arrest and ventricular fibrillation** | 472 | 1.98 (1.93–2.03) |
| Socioeconomic or psychosocial factors** | 354 | 1.78 (1.75–1.81) |
|
| ||
| Mental and substance use disorders, in remission** | 6 | 1.69 (1.64–1.75) |
| Other specified encounters and counseling** | 22 | 1.69 (1.67–1.72) |
| Stimulant-related disorders** | −189 | 1.65 (1.62–1.67) |
|
| ||
| Abdominal pain and other digestive or abdomen signs and symptoms | −66,456 | 0.93 (0.93–0.93) |
| Musculoskeletal pain, not low back pain | −52,150 | 0.81 (0.81–0.82) |
| Essential hypertension | −45,184 | 1.11 (1.10–1.11) |
| Nausea and vomiting | −38,536 | 0.85 (0.84–0.85) |
| Other specified upper respiratory infections | −36,189 | 0.82 (0.81–0.82) |
| Sprains and strains, initial encounter | −33,709 | 0.61 (0.61–0.62) |
| Superficial injury; contusion, initial encounter | −30,918 | 0.85 (0.84–0.85) |
| Personal or family history of disease | −28,734 | 1.21 (1.20–1.22) |
| Headache, including migraine | −27,458 | 0.85 (0.84–0.85) |
| Other unspecified injury | −25,974 | 0.84 (0.83–0.84) |
| Nonspecific chest pain | −24,258 | 1.20 (1.20–1.21) |
| Tobacco-related disorders | −23,657 | 1.19 (1.18–1.19) |
| Urinary tract infections | −23,346 | 1.02 (1.02–1.03) |
| Asthma | −20,660 | 0.91 (0.90–0.91) |
| Disorders of lipid metabolism | −20,145 | 1.12 (1.11–1.13) |
| Spondylopathies/Spondyloarthropathy (including infective) | −19,441 | 0.78 (0.77–0.79) |
| Otitis media | −17,852 | 0.35 (0.34–0.36) |
| Diabetes mellitus without complication | −15,893 | 1.10 (1.10–1.11) |
| Skin and subcutaneous tissue infections | −15,598 | 1.01 (1.00–1.02) |
| Chronic obstructive pulmonary disease and bronchiectasis | −15,520 | 1.05 (1.04–1.06) |
|
| ||
| Influenza | −12,094 | 0.16 (0.15–0.16) |
| No immunization or underimmunization | −1,895 | 0.28 (0.27–0.30) |
| Neoplasm-related encounters | −1,926 | 0.40 (0.39–0.42) |
| Intestinal infection | −5,310 | 0.52 (0.51–0.54) |
| Cornea and external disease | −9,096 | 0.54 (0.53–0.55) |
| Sinusitis | −7,283 | 0.55 (0.54–0.56) |
| Acute bronchitis | −15,470 | 0.59 (0.58–0.60) |
| Noninfectious gastroenteritis | −11,572 | 0.63 (0.62–0.64) |
Abbreviations: CI = confidence interval; COVID-19 = coronavirus disease 2019.
* The change in visits per week during the early pandemic and comparison periods was calculated as the difference in total visits between the two periods, divided by 4 weeks ([visits in diagnostic category, {early pandemic period} – visits in diagnostic category, {comparison period}] / 4).
† Analysis is limited to the 200 most common diagnostic categories. All eight diagnostic categories with an increase of >100 in the mean number of visits nationwide in the early pandemic period are shown. The top 20 categories with decreasing visit counts are shown.
§ Ratio calculated as the proportion of all ED visits in each diagnostic category during the early pandemic period, divided by the proportion of all ED visits in that category during the comparison period ([visits in category {early pandemic period}/all visits {early pandemic period})/(visits in category {comparison period}/all visits {comparison period}]). Ratios >1 indicate a higher proportion of visits in that category during the early pandemic period than the comparison period; ratios <1 indicate a lower proportion during the early pandemic than during the comparison period. Analysis is limited to the 200 most common diagnostic categories. The 10 categories with the highest and lowest ratios are shown.
¶ Florida, Hawaii, Louisiana, New York outside of New York City, Oklahoma, South Dakota, Wyoming, Santa Cruz and Solano counties in California, and the District of Columbia are not included.
** Top 10 highest prevalence ratios; higher proportion of visits in the early pandemic period than the comparison period.
†† Top 10 lowest prevalence ratios; lower proportion of visits in the early pandemic period than the comparison period.